Zoetis Inc.

NYSE:ZTS

Drug Manufacturers - General

Healthcare
$85.55 +1.51%

+$1.17 today

Market cap
$34.76B
Beta
0.74
P/E (TTM)
12.5
EPS (TTM)
$6.26
Dividend yield
2.63%
52W Low $72.38High $161.77

Volume 4.66M

Average 6.20M

ZTS Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Zoetis Inc.NYSE: ZTS

Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026

Capital expenditures declines year over year

Q2 FY2026 capital expenditures of $117M (cash outflow) fell 34.3% year over year, behind the -26.6% change in trailing-twelve-month capital expenditures. Sequentially, it rose 6.4% from the prior quarter. Over 3 fiscal years it compounded at +2.0% a year.

Context

  • Capital expenditures amounted to 6.6% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -34.3% toward the trailing-twelve-month pace of -26.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$117M+6.4% QoQ
Last fiscal yearDec 2025
-$621M-5.2% YoY
LTMJun 2026
-$521M-26.6% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-34.3%——
1 year-5.2%——
3-year CAGR+2.0%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(621M) USD
Year-over-year change
+5.2%

Capital Expenditures vs competitors

How ZTS compares with its peers on the latest reported figures

  • ZTS's LTM Jun 2026 capital expenditures of $521M is the 2nd largest of the 6 companies compared; the peer median is $114.99M.
  • Its year-over-year change of -26.6% is the 5th highest of 6, against a peer median of -14.5%.
  • Capital expenditures amounts to 5.5% of revenue for ZTS, versus a peer median of 4.0%.
ZTS Competitors Peer median
Capital Expenditures for ZTS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$3.9B +2.4%-2.1%5.9%
ZTSZoetis Inc.LTM Jun 2026$521M -26.6%+2.0%5.5%
ELANElanco Animal Health IncorporatedLTM Sep 2026$206M -22.8%+14.5%4.0%
IDXXIDEXX Laboratories, Inc.LTM Sep 2026$114.99M -14.5%-5.7%2.5%
PAHCPhibro Animal Health CorporationLTM Mar 2026$53.36M +39.6%+1.1%3.6%
NEOGNeogen CorporationLTM Aug 2026$35.5M -60.6%-7.9%4.0%
Peer median (excluding ZTS) $114.99M-14.5%-2.1%4.0%

Competitors are the stored peer set for ZTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income2.03B2.11B2.34B2.5B2.67B
Depreciation & Amortization448M465M491M497M487M
Deferred Income Tax(80M)(286M)(61M)(338M)(52M)
Stock-Based Compensation58M62M60M74M83M
Change in Working Capital(343M)(699M)(512M)79M(408M)
Accounts Receivables(155M)(137M)(102M)(61M)(236M)
Inventory(366M)(486M)(361M)(40M)(199M)
Accounts Payables(17M)(29M)13M31M46M
Other Working Capital195M(47M)(62M)149M(19M)
Other Non-Cash Items96M259M31M145M121M
Operating Cash Flow2.21B1.91B2.35B2.95B2.9B
Capital Expenditures(477M)(586M)(732M)(655M)(621M)
Acquisitions (Net)(14M)(312M)(59M)285M(24M)
Purchases of Investments(12M)(9M)(4M)(5M)(7M)
Sales of Investments44M23M12M62M0
Other Investing Activities1M1M6M(2M)(96M)
Investing Cash Flow(458M)(883M)(777M)(315M)(748M)
Debt Repayment(604M)1.35B(1.35B)(3M)2.27B
Common Stock Issued00000
Common Stock Repurchased(743M)(1.59B)(1.09B)(1.86B)(3.24B)
Dividends Paid(474M)(611M)(692M)(786M)(889M)
Other Financing Activities(45M)(49M)24M(13M)(14M)
Financing Cash Flow(1.86B)(904M)(3.11B)(2.66B)(1.87B)
Effect of Forex Changes(12M)(29M)(7M)(32M)39M
Net Change in Cash(119M)96M(1.54B)(54M)325M
Free Cash Flow1.74B1.33B1.62B2.3B2.28B

Zoetis Inc.

NYSE:ZTS

Intrinsic Alpha fair value

Locked

Current Price

$85.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.